BIXT Stock - Bioxytran, Inc.
Unlock GoAI Insights for BIXT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-7,950 | $-8,285 | $-3,644 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-2,223,068 | $-3,820,147 | $-2,134,112 | $-4,214,434 | $-1,268,701 |
| Net Income | $-2,366,681 | $-4,280,002 | $-2,463,932 | $-4,345,353 | $-3,754,444 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.02 | $-0.03 | $-0.02 | $-0.04 | $-0.04 |
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Visit WebsiteEarnings History & Surprises
BIXTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-0.00 | — | — |
Q3 2025 | Aug 11, 2025 | — | $0.00 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.02 | — | — |
Q2 2025 | Apr 3, 2025 | — | $-0.01 | — | — |
Q4 2024 | Oct 28, 2024 | — | $-0.00 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 19, 2024 | — | $-0.00 | — | — |
Q1 2024 | Mar 22, 2024 | — | $-0.01 | — | — |
Q4 2023 | Nov 2, 2023 | — | $-0.01 | — | — |
Q3 2023 | Jul 31, 2023 | — | $-0.01 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.01 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-0.01 | — | — |
Q2 2022 | May 23, 2022 | — | $-0.01 | — | — |
Q2 2022 | Apr 11, 2022 | — | $-0.01 | — | — |
Q4 2021 | Nov 17, 2021 | — | $-0.00 | — | — |
Q3 2021 | Aug 10, 2021 | — | $-0.01 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.02 | — | — |
Q2 2021 | Apr 9, 2021 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about BIXT
What is BIXT's current stock price?
What is the analyst price target for BIXT?
What sector is Bioxytran, Inc. in?
What is BIXT's market cap?
Does BIXT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BIXT for comparison